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Summary
Uncoupling protein 2 (UCP2) negatively regulates insulin secretion. UCP2 deficiency (by means of gene knockout) improves
obesity- and high glucose-induced b cell dysfunction and consequently improves type 2 diabetes in mice. In the present
study, we have discovered that the small molecule, genipin, rapidly inhibits UCP2-mediated proton leak. In isolated mito-
chondria, genipin inhibits UCP2-mediated proton leak. In pancreatic islet cells, genipin increases mitochondrial membrane
potential, increases ATP levels, closes KATP channels, and stimulates insulin secretion. These actions of genipin occur in
a UCP2-dependent manner. Importantly, acute addition of genipin to isolated islets reverses high glucose- and obesity-in-
duced b cell dysfunction. Thus, genipin and/or chemically modified variants of genipin are useful research tools for studying
biological processes thought to be controlled by UCP2. In addition, these agents represent lead compounds that comprise
a starting point for the development of therapies aimed at treating b cell dysfunction.Introduction
Uncoupling protein 2 (UCP2) is a mitochondrial carrier protein
with homology to other uncoupling proteins like UCP1 and
UCP3 (Fleury et al., 1997). UCP2 is expressed in a number of tis-
sues, includingpancreatic islets (Krauss et al., 2003; Zhanget al.,
2001). In previous studies, it has been demonstrated that UCP2
is a negative regulator of insulin secretion (Chan et al., 2001;
Zhang et al., 2001). UCP2 mediates proton leak across the inner
mitochondrial membrane. This has been demonstrated in stud-
ies using proteoliposomes (Echtay et al., 2001; Jaburek et al.,
1999), isolated mitochondria (Echtay et al., 2002), and in intact
cells (Krauss et al., 2002). In pancreatic b cells, UCP2-mediated
proton leak decreases the yield of ATP from glucose (Chan et al.,
2001; Zhang et al., 2001). Consequently, UCP2 negatively regu-
lates glucose-stimulated insulin secretion (Chan et al., 2001;
Zhang et al., 2001).
AsUCP2 is a negative regulator of insulin secretion, it has been
proposed that increased UCP2 expression in b cells could result
in b cell dysfunction and the development of type 2 diabetes.
Consistent with this idea, UCP2 mRNA and protein were found
to be markedly increased in pancreatic islets of animal models
of type 2 diabetes (Kassis et al., 2000; Laybutt et al., 2002; Win-
zell et al., 2003; Zhang et al., 2001). There is also evidence that
increased amounts of UCP2 expression in humans can downre-
gulate insulin secretion and increase the risk of type 2 diabetes
(Krempler et al., 2002; Sasahara et al., 2004; Sesti et al., 2003).CELL METABOLISM 3, 417–427, JUNE 2006 ª2006 ELSEVIER INC. DIt has been shown that UCP2 levels in islets are increased by
high glucose and high lipids in vitro (Laybutt et al., 2002; Patane
et al., 2002). Of note, gene knockout of UCP2 restores first-
phase insulin secretion, increases serum insulin levels, and
greatly decreases levels of glycemia in ob/ob mice (Zhang
et al., 2001). Furthermore, deficiency of UCP2 prevents obe-
sity-, high glucose-, and high lipid-induced b cell dysfunction
(Joseph et al., 2002, 2004; Krauss et al., 2003). Taken together,
these findings indicate that UCP2 is an important mediator of
b cell dysfunction. Consequently, a UCP2 inhibitor lacking
adverse side effects could be a potentially useful drug for treat-
ment of b cell dysfunction and type 2 diabetes. It is important to
note that, at present, no therapy exists for type 2 diabetes that is
specifically aimed at a pathogenic cause of b cell dysfunction.
The ‘‘classical’’ regulators of UCPs are fatty acids and purine
nucleotides. Purine nucleotides (ATP, ADP, GTP, and GDP) in-
hibit and fatty acids activate UCP2 and 3 when these are ex-
pressed in E. coli and reconstituted into liposomes (Echtay
et al., 2001; Jaburek et al., 1999; Zackova et al., 2003). Recently,
using mitochondria isolated from yeast and various rodent tis-
sues, Echtay et al. (2002) showed that UCP2 and 3 catalyze pro-
ton leak when activated by exogenously added superoxide. In
isolated mitochondria, purine nucleotides have been shown to
inhibit superoxide-induced, UCP2- or 3-dependent proton
leak (Echtay et al., 2002). However, purine nucleotides are not
cell permeable and therefore are unable to inhibit UCPs when
added to intact cells. The goal of the present study was toOI 10.1016/j.cmet.2006.04.010 417
A R T I C L EFigure 1. Chemical structure of genipin and effect of
genipin on superoxide-dependent proton leak of kid-
ney mitochondria isolated from wild-type and UCP2-
deficient mice
Chemical structure of genipin (A) and effect of geni-
pin on superoxide-dependent proton leak of kidney
mitochondria isolated from WT (B and C) and
UCP2-deficient (D and E) mice. Proton leak titrations
were performed in the presence (B and D) and ab-
sence (C and E) of a superoxide-generating system
(xanthine plus xanthine oxidase, +X/XO), essentially
as described previously (Krauss et al., 2003), and
with or without 50 mM genipin. Graphs show the
rate of proton leak as a function of its driving force,
mitochondrial membrane potential. Left panels (B
and D): filled triangles (:), control; open squares
(,), xanthine (50 mM) plus xanthine oxidase (0.2
mU/3.5 ml); filled diamonds (A), xanthine/xanthine
oxidase plus 50 mM genipin. Data are the means 6
SEM of three independent experiments with three
replicates per experiment. Right panels (C and E):
filled triangles (:), control; filled diamonds (A),
plus genipin. Data are the means 6 SEM of 8 repli-
cates.discover a UCP2 inhibitor capable of working in intact cells.
Such an agent would be an extremely useful investigational
tool for studying a number of aspects of UCP2 biology. In addi-
tion, a UCP2 inhibitor could theoretically represent a lead com-
pound for agents aimed at improving b cell function in type 2
diabetes.
Results
Stimulation of insulin secretion by Gardenia extract
and genipin
The extract of Gardenia jasminoides Ellis fruits has been used
over the years in traditional Chinesemedicine to treat symptoms
of type 2 diabetes (Danbuo, 1984; Wang, 1991). We evaluated
Gardenia extract and observed that it dose dependently stimu-
lated insulin secretion by pancreatic islets derived from wild-418type (WT) but not from UCP2-deficient mice (data not shown).
Because UCP2 was required for this effect, we assumed that
Gardenia extract contained a UCP2 inhibitor. To identify the ac-
tive molecule, Gardenia extract was fractionated using silica gel
chromatography (1:1 hexane and ethyl acetate as eluant). Frac-
tions were assessed for UCP2-dependent stimulation of insulin
secretion. Using proton NMR and mass spectroscopic analysis,
genipin was identified as a molecule within the active fraction.
The chemical structure of genipin was confirmed by comparison
with an authentic sample (Wako Chemicals USA, Inc.). Genipin,
obtained from the commercial supplier noted above, was further
tested for stimulation of insulin secretion (detailed studies for
genipin presented later). Genipin stimulated insulin secretion,
and this stimulation occurred with wild-type but not UCP2-defi-
cient islets. Figure 1A shows the chemical structure of genipin
(Djerassi et al., 1961).CELL METABOLISM : JUNE 2006
Genipin inhibits UCP2-mediated proton leakGenipin inhibits superoxide-activated, UCP2-mediated
mitochondrial proton leak
In order to assess the effect of genipin on superoxide-induced
UCP2-mediated proton leak, mitochondria were isolated from
kidneys of WT and UCP2-deficient mice, and proton leak was
measured in the presence or absence of exogenous superoxide
and genipin (Krauss et al., 2003). Exogenous superoxide was
generated in situ by adding the enzyme xanthine oxidase and
its substrate xanthine (+X/XO). In WT mitochondria, superoxide
activated proton leak as indicated by the leftward shift of the
proton leak titration curve (Figure 1B, +X/XO [,] versus control
[:]). Addition of genipin completely abolished superoxide-in-
duced proton leak (Figure 1B, +genipin, +X/XO [A] versus +X/
XO [,]). In mitochondria lacking UCP2, addition of superoxide
had no effect on proton leak (Figure 1D, +X/XO [,] versus con-
trol [:]). Genipin was without effect on proton leak when either
UCP2 (Figure 1D, +genipin, +X/XO [A] versus +X/XO [,]), or
superoxide (Figure 1C, +genipin [A] versus control [:]), or
both were absent (Figure 1E, + genipin [A] versus control
[:]). These results demonstrate that genipin inhibits superox-
ide-induced, UCP2-mediated proton leak. However, unknown
from these studies is whether genipin inhibits UCP2 activity di-
rectly or whether genipin interferes in some way with the path-
way by which superoxide activates UCP2.
Genipin does not scavenge superoxide
Genipin could inhibit UCP2-mediated proton leak by scavenging
superoxide. To evaluate this possibility, we assessed the effects
of genipin on an in vitro, cell-free superoxide generating system
(xanthine + xanthine oxidase plus salmon sperm DNA plus hy-
droethidine) (Zhao et al., 2003). Genipin did not decrease levels
of superoxide as observed by ethidium fluorescence, whereas
addition of the enzyme superoxide dismutase (MnSOD) com-
pletely abolished this signal (data not shown). Therefore, genipin
does not act as a superoxide scavenger.
Genipin inhibits HNE-activated, UCP2-mediated
mitochondrial proton leak
Recently, it has been proposed that superoxide-dependent acti-
vation of UCP-mediated proton leak occurs via aldehydic lipid
peroxidation intermediates such as 4-hydroxynonenal (HNE)
(Murphy et al., 2003), which has been shown to directly stimulate
UCP-dependent proton leak in isolated mitochondria (Echtay
et al., 2003). According to this model, aldehydic peroxidation
products such as HNE are generated as downstream products
in anactivation cascade, proximal toUCP2, andact as activators
ofUCP2-mediatedproton leak (Echtay et al., 2003;Murphy et al.,
2003). Thus, genipin could inhibit UCP2-mediatedproton leakby
interfering in a step in thepathwaybywhich superoxide activates
UCP2. In order to assess this possibility, we studied the effect of
genipin on HNE-induced UCP2-mediated proton leak in mito-
chondria isolated from kidney of WT and UCP2-deficient mice
(Echtay et al., 2003). In WT mitochondria, HNE activated proton
leak (Figure 2A, +HNE [,] versus control [:]). Preincubation of
mitochondria with genipin completely abolished HNE-induced
proton leak (Figure 2A, +genipin, +HNE [A] versus +HNE [,]).
In mitochondria lacking UCP2, addition of HNE had no effect
on proton leak (Figure 2B, +HNE [,] versus control [:]). Consis-
tent with experiments shown in Figure 1, genipin had little or no
effect on proton leak in mitochondria lacking UCP2 (Figure 2B,
+genipin, +HNE [A] versus +HNE [,]). Taken together, theseCELL METABOLISM : JUNE 2006results demonstrate that genipin inhibits HNE-induced, UCP2-
mediated proton leak. Thus, genipin does not interfere with the
pathway of activation of UCPs by superoxide but most likely in-
hibits UCP2 activity directly.
Genipin does not affect other mitochondrial transport
functions in liver mitochondria
In order to assess the potential effect of genipin on other mito-
chondrial carrier proteins,manyofwhich are 20%–30% identical
at the amino acid level to UCP2, and to assess effects on mito-
chondrial integrity in general,wemeasured respiration in isolated
mouse liver mitochondria using various respiratory substrates.
During state 3 respiration, fuel oxidation is coupled by ATP syn-
thase to the availability of exogenously added ADP (ADP stimu-
lates proton transport by ATP synthase, reducing backpressure
on proton pumps in the electron transport chain, hence stimulat-
ing respiration). Therefore, rates of respiration in state 3 are de-
pendent upon continued entry of fuels via various mitochondrial
carriers as well as the exchange of extramitochondrial ADP for
matrix ATP by the adenine nucleotide carriers. Note that UCP1
and its homologs, UCP2 and 3, are not expressed in liver under
normal physiological conditions (Pecqueur et al., 2001; Vidal-
Puig et al., 1997), therefore, any observed effects on liver mito-
chondrial activity would be UCP-independent. Using succinate
(Figure 2C) or malate-glutamate (Figure 2D) as substrate, respi-
ration in states 3and4wasassessed. In addition, totalmitochon-
drial respiratory capacity was determined by measuring respira-
tion following addition of 1 mM FCCP (a chemical uncoupler that
stimulates proton leak). Our results demonstrate that genipin
does not acutely affect state 3, state 4, or total (FCCP-stimu-
lated) respiration, indicating that genipin does not affect the
activity of the adenine nucleotide carrier or other mitochondrial
carriers involved in the metabolism of the substrates tested.
Genipin increases mitochondrial membrane potential,
increases ATP levels, closes KATP channels, and
stimulates insulin secretion in a UCP2-dependent
manner
We previously demonstrated that UCP2 regulates mitochondrial
membrane potential in intact cells. This was shown by demon-
strating that lack ofUCP2, or removal of endogenous superoxide
(a UCP2 activator), increasesmitochondrial membrane potential
in dispersed islet cells (Krauss et al., 2003). In the present study,
we investigated whether genipin induced changes in mitochon-
drialmembrane potential in dispersed islet cells, asmeasured by
the mitochondrial membrane potential–sensitive fluorescent
dye, TMRM (Figure 3A). Addition of genipin to dispersed islet
cells isolated fromWT animals induced a rapid increase in mito-
chondrial TMRM fluorescence over time. In contrast, addition of
genipin to dispersed islet cells lackingUCP2 had no effect onmi-
tochondrial TMRM fluorescence. The detected TMRM signal
was greatly reduced by addition of the chemical uncoupler,
FCCP, indicating that it accurately reportedmitochondrial mem-
brane potential. Thus, addition of genipin induced a rapid in-
crease in mitochondrial membrane potential in dispersed islet
cells, and this effect required the presence of UCP2. These find-
ings demonstrate that genipin inhibits UCP2-mediated proton
leak,which then leads to an increase inmitochondrialmembrane
potential.
An increase in mitochondrial membrane potential is predicted
to stimulate ATP production by ATP synthase and increase419
A R T I C L EFigure 2. Effect of genipin on HNE-induced proton
conductance of kidney mitochondria isolated from
wild-type and UCP2-deficient mice and effect of
genipin on state 3, state 4, and FCCP-uncoupled res-
piration in liver mitochondria isolated from wild-type
mice
Effect of genipin on HNE-induced proton conduc-
tance of kidney mitochondria isolated from WT (A)
and UCP2-deficient mice (B) and effect of genipin
on state 3, state 4 and FCCP-uncoupled respiration
in livermitochondria isolated fromWTmice (C andD).
A and B) Proton leak titration was performed with
addition of 35 mM HNE essentially as described pre-
viously (Echtay et al., 2003) and in Experimental Pro-
cedures, and with or without 50 mM genipin. Graphs
show the rate of proton leak as a function of its driv-
ing force, mitochondrial membrane potential. Filled
triangles (:), control; open squares (,), HNE (35
mM); filled diamonds (A), HNE plus 50 mM genipin.
Proton leak data are the means 6 SEM of three
independent experiments with three replicates per
experiment.
C and D) Potential effects of genipin on state 3 and
state 4 respiration in isolated liver mitochondria
was assessed in the presence of 4 mM succinate
(C) or 8 mM glutamate/malate (D), with or without
50 mM genipin. State 3 and 4 respiration was mea-
sured within 20 min of genipin addition, and data
were normalized to the state 3 condition for each
substrate without genipin present. Data are the
means 6 SEM of three independent experiments
with three replicates per experiment.levels of ATP. This was tested by assessing effects of genipin
on ATP levels in incubated islets. As is shown in Figure 3B,
genipin increased ATP levels in WT islets but not in islets
isolated from UCP2-deficient mice. In contrast, 20 mM glucose
increased ATP levels in both WT and UCP2-deficient islets.
Thus, acute inhibition of UCP2 increases ATP levels in islet
cells.
In pancreatic b cells, ATP closes plasma membrane KATP
channels which depolarizes the cell, opening voltage gated cal-
cium channels, ultimately stimulating insulin secretion. In the
present study, we assessed whether acute inhibition of UCP2
by genipinwould, as predicted, close KATP channels. To address
this issue, currents (Figure 3C(ii), bottom tracing) were recorded
in response to alternate620 mV voltage steps (Figure 3C(ii), top
tracing) from a holding potential of 270 mV, using the ‘‘perfo-
rated-patch’’ configuration (Sakura et al., 1998). To evaluate
the density of KATP channels, currents (pA) were recorded in
the presence of zero glucose andwere normalized to cell capac-
itance (pF) to control for possible differences in cell size. These
studies indicated that the density of KATP channels is similar in
wild-type versus UCP2-deficient cells (pA/pF, mean 6 SE,
WT= 12.86 1.8 [n = 5], UCP22/2 = 13.26 2.2 [n = 5]). Represen-
tative current traces showing the effects of glucose, genipin,
and tolbutamide (specific KATP channel blocker) are shown in420Figure 3C(i) and the summary of these recordings is shown in
Figure 3C(iii). As can be seen, genipin closed KATP channels in
WT but not in UCP2-deficient cells. The absence of an effect of
genipin in cells lacking UCP2 argues against a direct effect of
genipin on KATP channels. In contrast, both 10 mM glucose and
tolbutamide closed KATP channels in both WT and UCP2
2/2
cells, indicating that KATP channels function normally in UCP2-
deficient cells. Thus, inhibition of UCP2 by genipin increases
mitochondrial membrane potential, increasing the level of ATP,
which then closes KATP channels.
UCP2 is a negative regulator of insulin secretion (Zhang et al.,
2001). Thus, deficiency of UCP2 increases insulin secretion
in vitro and in vivo (Krauss et al., 2003; Zhang et al., 2001). In
the studies above, we show that genipin inhibits UCP2 activity
in isolated mitochondria and intact cells. Thus, it is predicted
that genipin would stimulate insulin secretion. We therefore as-
sessed whether genipin affects insulin secretion in islets (Fig-
ure 4). Genipin dose dependently increased insulin secretion
in WT islets (Figure 4, left panel). In contrast, genipin had no ef-
fect in islets deficient in UCP2 (Figure 4, right panel). Taken to-
gether, these studies show that genipin acutely inhibits UCP2
activity, which then increases mitochondrial membrane poten-
tial, increases ATP levels, closes KATP channels, and conse-
quently, stimulates insulin secretion.CELL METABOLISM : JUNE 2006
Genipin inhibits UCP2-mediated proton leakFigure 3. Effects of genipin on islet cell mitochon-
drial membrane potential and KATP channel activity
A) Effect of genipin on mitochondrial membrane po-
tential in islet cells. Relativemitochondrial membrane
potential was calculated based on TMRM fluores-
cence inWT andUCP2-deficient dispersed islet cells
as described in Supplemental Data. TMRM-loaded
cells were imaged for 10 min prior to addition of 10
mM Genipin and then for a further 10 min before
and then 10 min after addition of 2 mM FCCP as indi-
cated. Results are expressed as the means 6 SEM
of three individual experiments (R12 cells per exper-
iment).
B) Glucose- and genipin-induced changes in ATP
levels in wild-type and UCP2-deficient islets. Follow-
ing overnight culture, islets were preincubated for 30
min in 5 mM glucose and then incubated again in
KRHB buffer containing 5 mM, 20 mM glucose, or
5 mM glucose plus 10 mM genipin. Islet ATP content
was determined by luciferin-luciferase biolumines-
cent assay as described in Experimental Proce-
dures. Results are expressed as means 6 SEM of
three individual experiments with three replicates
per experiment. ***p < 0.001, treated versus un-
treated control (i.e., 5 mM glucose group) (unpaired,
two-tailed t test).
C) Effect of glucose (10 mM) and genipin (10 mM) on
KATP channel currents in islet cells. Electrophysiolog-
ical recordings were performed in the ‘‘perforated
patch’’ mode as described in Experimental Proce-
dures. Currents were recorded in response to alter-
nate voltage steps (620 mV, 200 ms) from a holding
potential of 270 mV. [C(i)] Representative current
traces encompassing the 20 min recording period
for wild-type (WT) and UCP22/2 cells. In sequential
order (as indicated), cells were exposed to 2mM glu-
cose/ 10mM glucose/ 2mM glucose/ genipin
(10 mM) plus 2 mM glucose/ 2 mM glucose/ tol-
butamide (0.2 mM) plus 2 mM glucose/ 2 mM glu-
cose. [C(ii)] Two alternate voltage steps (above) and
the current responses (below) in a wild-type cell ex-
posed to 2 mM glucose. [C(iii)] Summary of KATP
channel currents in response to glucose, genipin,
and tolbutamide. Current amplitudes for each condi-
tion were averaged over 1–3 min intervals during
which current amplitudes were stable. The current
amplitude was normalized to its own basal value (2
mM glucose) and was then plotted as remaining cur-
rent (%). Data represent mean 6 SEM (WT cells, n =
6; UCP22/2 cells, n = 5). *p < 0.05, wild-type versus
UCP22/2 cells (unpaired, two-tailed t test).Genipin reverses high glucose- and obesity-induced
b cell dysfunction
Impaired secretion of insulin by pancreatic b cells, together with
resistance to insulin action, causes type 2 diabetes. A large body
of work has established that chronic hyperglycemia and obesity
cause loss of glucose-stimulated insulin secretion (GSIS) (Mat-
thews and Clark, 1997; Robertson, 2000). We have shown that
deficiency of UCP2, or removal of endogenously produced
superoxide (a UCP2 activator), prevents high glucose- and
obesity-induced loss of GSIS (Krauss et al., 2003). Here, we as-
sessed the effect of genipin on high glucose- and obesity-
induced b cell dysfunction. Pancreatic islets were isolated from
WT (Figure 5A) or UCP2 KO mice (Figure 5B) and subjected to
chronic incubations (48 hr) in low (5.5 mM) or high (25 mM)
glucose. Following chronic incubation, islets were washed and
insulin-secretion studies were performed using three different
concentrations of glucose (5.5, 12.5, and 25mM), with orwithout
genipin present (5 mM).CELL METABOLISM : JUNE 2006WT islets incubated chronically at low glucose released in-
creasing amounts of insulin in response to increasing concentra-
tions of glucose (Figure 5A, left panel). Following chronic incuba-
tion in high glucose, islets increased basal insulin release but
were completely unresponsive to glucose stimulation (Figure
5A, middle panel). These data are consistent with other reports
and our previous results (Krauss et al., 2003) showing that
chronic high glucose increases basal insulin secretion and, at
the same time, causescomplete lossof glucose responsiveness.
To assess whether genipin could restore high glucose-induced
loss of glucose responsiveness, we acutely added 5 mM genipin
to islets during the insulin-release portion of the study. Acute ad-
dition of genipin reversed the high glucose-induced block in
GSIS (Figure 5A, right panel). To see whether this effect of geni-
pin was mediated by UCP2, islets were isolated from UCP2 KO
mice and then incubated in chronic high glucose. Following
chronic incubation in low glucose (5.5 mM), UCP2 KO islets,
likeWT islets, released increasing amounts of insulin in response421
A R T I C L Eto increasing concentrations of glucose (Figure 5B, left panel).
UnlikeWT islets, however, islets fromUCP2KOmice,when incu-
bated chronically at 25 mM glucose, retained glucose respon-
siveness (Figure 5B, middle panel). In addition, genipin reduced
the elevation in basal insulin secretion. Their pattern of response
was similar to that observed in WT islets incubated with genipin
(Figure 5A, right panel). Importantly, in UCP2 KO islets, genipin
had no additional beneficial effect on GSIS (Figure 5B, right
panel), indicating that improved glucose responsiveness is
caused by genipin-dependent inhibition of UCP2.
Because absence of UCP2 in ob/ob islets restores glucose
sensing, and because removing the activator of UCP2 (superox-
ide) in dysfunctional islets similarly restores islet function (Krauss
et al., 2003; Zhang et al., 2001), we reasoned that genipin (as an
inhibitor of UCP2) would reverse obesity-induced b cell dysfunc-
tion. Thus, we studied insulin secretion in islets from ob/obmice
and from ob/ob mice lacking UCP2 in the absence or presence
of genipin. Islets from ob/obmice showed elevated basal insulin
secretion and loss of glucose responsiveness compared with
WT islets (Figure 5C, first set of bars, versus Figure 5A, left
panel), similar to what was observed in WT islets following
chronic high-glucose treatment (Figure 5A, middle panel). Gen-
ipin acutely restored glucose sensing in ob/ob islets (Figure 5C,
second set of bars). In addition, genipin reduced the elevation in
basal insulin secretion. Islets isolated from ob/ob mice lacking
UCP2 were responsive to glucose (Figure 5C, third set of
bars), similar to ob/ob islets treatedwith genipin, and also similar
toWT islets treatedwith genipin (Figure 5A, right panel) or UCP2-
deficient islets during exposure to high glucose (Figure 5B, mid-
dle panel). Of note, islets from ob/obmice lacking UCP2 treated
with genipin did not improve glucose sensing above the level
seen in islets lacking UCP2 alone (Figure 5C, last set of bars).
Therefore, genipin acutely improves the significant obesity-in-
duced impairment of GSIS.
A genipin derivative, 1, 10-anhydrogenipin (AG), inhibits
proton leak, inhibits KATP channels, and stimulates
insulin secretion in a UCP2-dependent manner
Genipin is a naturally occurring protein cross-linking agent (Fuji-
kawa et al., 1988; Huang et al., 1998). To investigate if this action
Figure 4. Effect of genipin on insulin secretion from isolated islets
Pancreatic islets were isolated from WT and UCP2 KO mice. Islets were treated
with different doses of genipin, which was present during the one hour insulin re-
lease study. Concentration of glucose was 5.5 mM. Results are the means6 SEM
of four independent experiments with eight replicates per experiment. *p < 0.05,
treated versus untreated control; #p < 0.05, UCP2-deficient control versus WT
control (unpaired, two-tailed t test).422of genipin is required for inhibition of UCP2,we set out to synthe-
size a derivative of genipin that lacks cross-linking activity. It has
been reported that genipin can be dimerized by equimolar
amounts of glycine to form the blue pigment, genipocyanin G1,
a highly conjugated dimeric adduct (Figure 6A, structure 1) (Fuji-
kawa et al., 1987). It has also been reported that cytochrome c
can be cross-linked by genipin to form oligomers and that the
cross-linking process likely involves formation of complexes in
which two primary amine groups from separate proteins react
Figure 5. Effect of genipin on chronic high glucose- and obesity-induced b cell
dysfunction
Pancreatic islets were isolated fromWT (A) or UCP2 KOmice (B) and subjected to
chronic incubations at low (5.5 mM) and high (25 mM) glucose. Islets were incu-
bated for a total of 48 hr and washed, and then insulin-secretion studies were per-
formed using three different concentrations of glucose (5.5, 12.5, and 25 mM) with
or without 5 mM genipin. In a separate experiment, islets were isolated from ob/ob
mice (C). ob/ob islets were incubated in RPMI (11 mM glucose) overnight, then
washed, and insulin-secretion studies were performed using three different con-
centrations of glucose (5.5, 12.5, and 25 mM) with or without 5 mM genipin. In
(A) and (B), results are the means 6 SEM of four independent experiments with
eight replicates per experiment. In (C), results are the means6 SEM of 10–20 rep-
licates. *p < 0.05, 12.5 mM or 25 mM glucose versus 5.5 mM glucose (unpaired,
two-tailed t test).CELL METABOLISM : JUNE 2006
Genipin inhibits UCP2-mediated proton leakFigure 6. Effects of the genipin derivative, 1, 10-an-
hydrogenipin on superoxide-dependent proton leak
of kidney mitochondria
A) Proposed mechanism by which genipin cross-
links proteins, (B) chemical structure of the genipin
derivative, 1, 10-anhydrogenipin (AG), and (C and
D) effect of AG on superoxide-dependent proton
leak of kidney mitochondria isolated from WT mice.
Proton leak titrationswere performed in the presence
(C) and absence (D) of a superoxide-generating sys-
tem (xanthine plus xanthine oxidase) with or without
50 mM AG. Left panel (C): filled triangles (:), control;
open squares (,), xanthine plus xanthine oxidase
(X/XO); filled diamonds (A), AG plus X/XO. Right
panel (D): filled triangles (:), control; filled diamonds
(A), plus AG. Proton leak data are the means6 SEM
of six to eight replicates.with genipin (Figure 6A, structure 2) (Fujikawa et al., 1988). As the
C10 primary alcohol and the C1 hemiacetal of genipin are likely
required for the formation of the oligomeric products (Touyama
et al., 1994), it is conceivable that genipin derivatives lacking
these two active sites may lose cross-linking activity. To confirm
this prediction, a dehydrated derivative, 1,10-anhydrogenipin
(AG, Figure 6B)was prepared fromgenipin.Weperformed a sim-
ple color assay by treating the synthetic derivative, AG, or geni-
pin, with an equimolar amount of glycine in pH 7 buffer at 80ºC.
After 4 hr, the AG solution, but not the genipin solution, was still
clear, which indicates that dimerization to form conjugated gen-
ipocyanin G1-type blue pigments did not occur with AG. To con-
firm that AG lacks protein cross-linking activity, the previously
described cytochromeccross-linking assaywasperformed (Fu-
jikawa et al., 1988) with genipin and AG. This study, shown in the
SupplementalData availablewith this article online, revealed that
genipin but not AG oligomerizes cytochrome c. Thus, as pre-
dicted, AG lacks protein cross-linking activity.
We then assessed the effects of AG on (1) UCP2-mediated
proton leak in isolated mitochondria, on (2) KATP channel activity
in dispersed islet cells, and on (3) insulin secretion from isolated
islets. As previously observed, superoxide stimulates proton
leak (Figure 6C, +X/XO [,] versus control [:]). As with genipin,
AG inhibited superoxide-stimulated proton leak (Figure 6C, +AG,
+X/XO [A] versus +X/XO [,]). Also, like genipin, AG had no ef-
fect on proton leak when superoxide was absent (Figure 6D,
+AG [A] versus control [:]). As shown in Figure 7A, AG inhibited
KATP channel activity in wild-type cells but not in UCP2-deficient
cells. Finally, as shown in Figure 7B, AG stimulated insulin secre-
tion in wild-type islets but not in UCP2-deficient islets. Compar-
ison between the effects of genipin and AG, at the same doses,
on KATP channel activity (10 mM) and on insulin secretion (5 mM,
genipin data from Figure 4 plotted again in Figure 7B to facilitateCELL METABOLISM : JUNE 2006comparison) raises the possibility that AG,while having the same
activities as genipin,may be less potent. This apparent decrease
in potency could be due to loss of cross-linking activity but more
likely is related to other properties of AG that may affect its solu-
bility, its ability to cross membranes, or possibly its interaction
with UCP2. Additional studies are necessary to differentiate
these possibilities. Despite these issues, these findings suggest
that protein cross-linking activity is not required for inhibition of
UCP2 by genipin-related compounds.
Discussion
In the present study, we identified a molecule, genipin, which in-
hibits UCP2-mediated proton leak. In isolated kidney mitochon-
dria, genipin specifically inhibits UCP2-mediated proton leak. In
pancreatic islets, genipin increases mitochondrial membrane
potential, increases ATP levels, closes plasma membrane KATP
channels, and stimulates insulin secretion in a UCP2-dependent
manner. Importantly, acute inhibition of UCP2 by genipin re-
verses high glucose- and obesity-induced b cell dysfunction.
Prior to this discovery, purine nucleotides (ATP, ADP, GTP,
and GDP) were the only known inhibitors of UCPs (Echtay
et al., 2001; Jaburek et al., 1999; Zackova et al., 2003). However,
purine nucleotides are impermeable to cell membranes and
therefore are not useful for studies in whole cells or animals. Su-
peroxide is an important, physiologically relevant regulator of
UCPs (Echtay et al., 2003). Recently, it has been proposed
that superoxide-dependent activation of UCP-mediated proton
leak occurs via aldehydic lipid peroxidation intermediates such
as 4-hydroxynonenal (HNE) (Murphy et al., 2003), which have
been directly shown to stimulate UCP-dependent proton leak
in isolated mitochondria (Echtay et al., 2003). Our results show
that genipin inhibits HNE-induced, UCP2-mediated proton423
A R T I C L EFigure 7. Effects of 1, 10-anhydrogenipin on KATP
channel currents and insulin secretion
A) Effects of AG on KATP channel currents. Electro-
physiological recording were performed in the ‘‘per-
forated patch’’ modes as was done in Figure 3C. Left
panel: representative tracings from wild-type (WT)
and UCP22/2 cells. In sequential order (as indicated),
cells were exposed to 2 mM glucose/ AG (10 mM)
plus 2 mM glucose/ 2 mM glucose/ tolbutamide
(0.2 mM) plus 2 mM glucose/ 2 mM glucose. Right
panel: summary of KATP channel currents in re-
sponse to AG and tolbutamide. Current amplitudes
for each condition were averaged over 1–3 min inter-
vals during which current amplitudes were stable.
The current amplitude was normalized to its own
basal value (2 mM glucose) and was then plotted
as remaining current (%). Data represent mean 6
SEM (WT cells, n = 5; UCP22/2 cells, n = 4). *p <
0.05, wild-type versus UCP22/2 cells (unpaired,
two-tailed t test).
B) Effects of AG on Insulin secretion. Pancreatic is-
lets were isolated fromWT and UCP2 KOmice. Islets
were treated with vehicle (control), genipin (5 mM) or
AG (5 mM) during the 1 hr insulin release study. Con-
centration of glucose was 5.5 mM. Note, genipin
data shown above is from Figure 4 and is plotted
again here to facilitate comparison between AG
and genipin. Results are the means6 SEM of four in-
dependent experiments with eight replicates per ex-
periment. *p < 0.05, treated versus untreated control;
#p < 0.05, UCP2-deficient control versus WT control
(unpaired, two-tailed t test).leak, suggesting that genipin does not inhibit UCP2 by interfer-
ing with upstream components of the suggested superoxide ac-
tivation pathway. Thus, we speculate that genipin inhibits
UCP2-mediated proton leak by directly interacting with UCP2.
Given the high degree of homology between UCP2 and UCP3,
genipin may also inhibit UCP3-mediated proton leak. Our pre-
liminary studies indicate that this could be the case. However,
additional work is required to confirm this possibility.
Genipin is a naturally occurring cross-linking agent. It is theo-
retically possible that the cross-linking activity of genipin could
be required for inhibition of UCP2. In addition, the cross-linking
activity could produce adverse, nonspecific effects due to inter-
action with other proteins. For these reasons, we synthesized
a genipin derivative, AG (Figure 6B), that lacks protein cross-
linking activity. Of interest, AG inhibits UCP2-mediated proton
leak, closes KATP channels, and stimulates insulin secretion in
a UCP2-dependent fashion. These results suggest that the
cross-linking activity of genipin is not required for its biological
activity as a UCP inhibitor.
A PubMed (http://www.ncbi.nlm.nih.gov/entrez/query.fcgi)
search for papers on genipin suggests a variety of activities for
this compound. It is possible that these other activities are sec-
ondary to inhibition of UCP2. This possibility could be critically
tested by using UCP2-deficient animals and cells to determine
if the presence of UCP2 was required for these effects. Alterna-
tively, and more likely given what is known about the biology of
UCP2, these other activities are probably unrelated to inhibition
of UCP2. This contention is supported by the fact that most of
these other activities are observed at concentrations of genipin
significantly higher than those employed in the present study.
This raises the possibility that these other actions may be medi-424ated by the cross-linking activity of genipin. If this is the case,
then derivatives of genipin, like AG, that lack cross-linking activ-
ity but retain UCP2-inhibiting activity, could be useful UCP2 in-
hibitors.
b cells sense glucose through its metabolism and the resulting
increase in ATP, which closes KATP channels depolarizing the
cell, increasing Ca2+ influx, ultimately stimulating insulin secre-
tion. Uncoupling protein 2 (UCP2) mediates mitochondrial pro-
ton leak, decreasing ATP production. It has previously been es-
tablished that UCP2 negatively regulates glucose-stimulated
insulin secretion (Chan et al., 2001; Zhang et al., 2001). Of path-
ophysiologic significance, UCP2 was markedly upregulated in
islets of ob/ob mice (Zhang et al., 2001), a model of obesity-in-
duced diabetes. Importantly, ob/ob mice lacking UCP2 had re-
stored first-phase insulin secretion, increased serum insulin
levels, and greatly decreased levels of glycemia (Zhang et al.,
2001). These results establish UCP2 as a critical link between
obesity, b cell dysfunction, and type 2 diabetes. Recently, we
have demonstrated that endogenously produced superoxide
activates UCP2 (Krauss et al., 2003). Interruption of the superox-
ide-UCP2 pathway improves high glucose- and obesity-in-
duced impairment of glucose-stimulated insulin secretion
(GSIS) (Krauss et al., 2003). In the present study, we demon-
strate that acute exposure to genipin reverses high glucose-
and obesity-induced loss of GSIS. A novel feature of the present
study is the rapidity of this effect. Importantly, genipin is without
effect in islets lacking UCP2, indicating that genipin’s ability to
reverse high glucose- and obesity-induced b cell dysfunction
is explained by its ability to inhibit UCP2.
Exposure to either chronic high glucose or the obese state
produces an elevation in basal insulin secretion, in addition toCELL METABOLISM : JUNE 2006
Genipin inhibits UCP2-mediated proton leakcausing loss of glucose sensing. This has previously been ob-
served by us (Krauss et al., 2003) and others (Bjorklund et al.,
2000; Patane et al., 2002). Chronic exposure to free fatty acids
similarly elevates basal insulin secretion while causing loss of
glucose sensing (Joseph et al., 2004). The reason why basal se-
cretion is elevated in these states of b cell dysfunction is not
known. It is interesting to note that inhibition of UCP2 by means
of gene knockout (Joseph et al., 2004; Krauss et al., 2003), re-
moval of superoxide (Krauss et al., 2003), or genipin (present
study) improves both abnormalities (i.e., the increased basal in-
sulin secretion and the loss of glucose-stimulated insulin secre-
tion). Just as it is unknownwhy these states cause an increase in
basal insulin secretion, it is similarly unknown why inhibition of
UCP2 corrects this abnormality. One possible explanation is
that increased UCP2 activity, associated with states of b cell
dysfunction, impairs the ability of the cell to keep cytosolic
Ca2+ concentrations low. This could happen because increased
UCP2 activity reduces ATP levels, which powers Ca2+-ATPases
to pump Ca2+ out of the b cell and also into the endoplasmic re-
ticulum (Rizzuto and Pozzan, 2006). In addition, increased UCP2
activity reduces themitochondrial membrane potential, the driv-
ing force for Ca2+ entry into mitochondria. Consistent with this
possibility, it has previously been shown that chronic hypergly-
cemia markedly elevates basal cytosolic Ca2+ concentrations
(Bjorklund et al., 2000; Taylor et al., 2005). If this hypothesis is
correct, then inhibition of UCP2 in states of b cell dysfunction
would be expected to reduce basal cytosolic Ca2+ concentra-
tions and hence basal insulin secretion while, at the same
time, restoring glucose-stimulated insulin secretion. This hy-
pothesis, regarding the role of increased UCP2 activity in aug-
menting basal insulin secretion in states of b cell dysfunction,
will need to be evaluated in future studies.
Impaired glucose-stimulated insulin secretion by pancreatic
b cells, together with resistance to insulin action, causes type
2 diabetes. Current treatment for diabetes mellitus begins with
diet and exercise. However, compliance can be poor and, as
the disease progresses, treatment with sulfonylureas, thiazolidi-
nediones, or metformin, is often necessary. Of interest, none of
these pharmacologic treatments are specifically directed at
a pathogenic cause of pancreatic b cell dysfunction. Also, in
many patients, these pharmaceutical agents prove inadequate
for maintaining blood glucose at an acceptable level and injec-
tion with insulin is necessary. Therefore, a need exists for new
therapies, and in particular, agents that specifically target pan-
creatic b cell dysfunction. Given that increased UCP2 activity
in pancreatic b cells causes high glucose- and obesity-induced
loss of glucose sensing, and that genipin inhibits UCP2 activity
and acutely improves high glucose- and obesity-induced
b cell dysfunction, genipin or analogs of genipin represent lead
compounds that comprise a novel starting point for the develop-
ment of therapies aimed at a pathogenic cause of pancreatic
b cell dysfunction.
Experimental procedures
Isolation of mitochondria, proton leak titrations, and mitochondrial
respiration studies
See Supplemental Data for detailed methodology.
Preparation of dispersed islet cells and imaging of mitochondrial
membrane potential
See Supplemental Data for detailed methodology.CELL METABOLISM : JUNE 2006Patch-clamp electrophysiology
Experiments were carried out on dispersed islet cells, using the perforated-
patch configuration, which retains cell metabolism intact (Sakura et al.,
1998). Currents flowing through KATP channels were monitored using alter-
nate 20 mV pulses of 200 ms duration from a holding potential of 270 mV.
Pulses were applied every 2 s. Whole-cell currents were recorded using
aMultiClamp 700BAmplifier and pClamp 9.2 software (Axon Instrument). Re-
cording electrodes had resistances of 2.5–4MUwhen filled with the following
solution: containing 70 mM K2SO4, 10 mM NaCl, 10 mM KCl, 21 mM MgCl2,
10 mMHEPES, and 40 mM sucrose (pH 7.2 with KOH). For perforated-patch
recordings, 0.15–0.2 mg/ml amphotericin B was added to the pipette solu-
tion. The standard external solution consisted of: 140 mM NaCl, 5.6 mM
KCl, 1.2 mM MgCl2, 2.6 mM CaCl2, 10 mM HEPES, and 2 mM glucose (pH
7.4 with NaOH). Bath solutions containing either 2 mM glucose, 10 mM glu-
cose, or 2 mM glucose plus 10 mMgenipin, 10 mMAG (1,10-anhydrogenipin),
or 0.2 mM tolbutamide were applied to the recording chamber through per-
fusion. All experiments were carried out at room temperature (22ºC –24ºC).
ATP measurements
Following overnight culture inRPMI 1640 (11mMglucose, 7.5%FCS, and1%
penicillin-streptomycin), batches of five size-matched islets were preincu-
bated for 30 min in 1 ml KRHB containing 5 mM glucose and then incubated
for 1 hr in 1 ml KRHB containing either 5 or 20 mM glucose or 5 mM glucose
plus 10 mM genipin. At the end of this incubation, islets were disrupted with
trichloracetic acid (5% vol/vol final) and vortexed for 10 s. Following a 5 min
incubation on ice, extracts were centrifuged (10,000 3 g, 5 min) at 4ºC. The
supernatant (400ml) wasmixedwith 1.5ml of diethyl ether and the ether phase
containing the trichloroacetic acid was discarded. This step was repeated
a further three times. Extracts were diluted with 400 ml of buffer containing
20 mMHEPES, 3 mMMgCl2, (pH 7.75), and stored at280ºC. ATP was mea-
sured in duplicate using a luciferin-luciferase bioluminescent assay (Sigma).
Light emission was recorded for 30 s using a photon counting luminometer
(Victor2; PerkinElmer,Wellesley,Massachusetts). ATP concentrationwas ob-
tained by comparison to known standards (0–100 pmol) prepared in parallel
with the cell extracts.
Islet insulin secretion
Islets were isolated as previously described (Krauss et al., 2003) and incu-
bated overnight in RPMI 1640 (11 mM glucose, supplemented with 7.5%
FCS and 1%penicillin-streptomycin). On the next day, islets were transferred
into DMEM (5.5 mM glucose plus 0.1% gelatin) with or without genipin (0 nM,
50 nM, 0.5 mM, or 5 mM) or the derivative AG (5 mM). After 1 hr of incubation,
medium was removed for measurement of insulin concentrations. Insulin
levels in the medium were determined as described previously (Zhang
et al., 2001) except that a rat-insulin ELISA kit (Crystal Chem Inc., Chicago,
Illinois) was used.
Islet incubation in chronic high glucose
Isolation of islets and incubation conditions
Islets were isolated and incubated overnight as described above. On the next
day, all islets were transferred to RPMI 1640 (5.5 or 25 mM glucose, 7.5%
FCS) and incubated for 48 hr at 37ºC. After chronic incubation, all islets
were washed three times with DMEM. Medium-sized islets (of the same
size) were used for determination of insulin release. For each of the different
conditions (chronic incubation at 5.5 and 25 mM glucose), three islets were
transferred to an Eppendorf tube containing 1 ml of fresh DMEM (5.5, 12.5,
and 25 mM glucose plus 0.1% gelatin) with or without 5 mM genipin and in-
cubated at 37ºC for 1 hr. For each condition in every experiment, 5–8 repli-
cates were studied (i.e., 5–8 Eppendorf tubes, each containing 3 islets). After
1 hr of incubation, an aliquot of medium was removed for insulin assay.
Insulin-secretion studies in ob/ob islets
ob/obmice lacking UCP2were created as described previously (Zhang et al.,
2001, Krauss et al., 2003). Male mice aged 16–20 weeks were used for islet
studies. For each genotype, islets from three mice were pooled for insulin-re-
lease studies. After being isolated and incubated overnight in RPMI, 11 mM
glucose, the islets were washed three times with DMEM and then placed into
Eppendorf tubes (1 islet per tube), with each tube containing 1 ml of fresh
DMEM (5.5, 12.5, and 25 mM glucose plus 0.1% gelatin) with or without
5 mM genipin, and incubated at 37ºC for 1 hr. Islets of similar size were425
A R T I C L Eused for determination of insulin release with 5–10 replicates analyzed per
condition. Multiple experiments were performed. The results of a representa-
tive experiment are shown in Figure 5C.
Genipin and 1,10-anhydrogenipin
Genipin was obtained from Wako Chemicals USA (http://www.wakousa.
com, catalog # 078-0302). Preparation of 1,10-anhydrogenipin (AG): Genipin
(5 g, 22.1mmol) and triphenylphosphine (6085mg, 23.2mmol)weredissolved
in 110ml of distilled methylene chloride. To the solution at 0ºC was added di-
isopropyl azodicarboxylate (4.60ml, 23.2mmol) dropwise. The resultingmix-
ture was stirred at the same temperature for 30 min. Concentration in vacuo
andpurificationonsilicagel usinghexane/EtOAc (10:1–4:1) as eluant afforded
1.9 g of AG as a white solid (41% yield, >99% purity). IR (neat): 2950, 1700,
1634, 1437, 1287, 1189, 1075, 1038, 891 cm-1; 1H NMR (400 MHz, CDCl3):
d 7.48 (1 H, s), 5.54 (1H, br s), 5.30 (1H, d, J = 4.4 Hz), 4.45 (1H, br d, J =
12.8 Hz), 4.36 (1H, br d, J = 12.8 Hz), 3.71 (3H, s), 3.62 (1H, br s), 3.27 (1H,
dd, J = 14.4, 6.8 Hz), 3.22 (1H, br d, J = 16.0 Hz), 2.69 (1H, br d, J = 16.0 Hz)
ppm; 13C NMR (100 MHz, CDCl3): d 167.7, 153.0, 143.3, 121.6, 107.7, 96.0,
64.7, 54.5, 51.0, 46.2, 32.1 ppm; HRMS (CI): calculated. for C11H12O4
208.0736, found 208.0696.
Supplemental data
Supplemental data include Supplemental Experimental Procedures, one fig-
ure, and Supplemental References and can be foundwith this article online at
http://www.cellmetabolism.org/cgi/content/full/3/6/417/DC1/.
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